<DOC>
	<DOCNO>NCT00201435</DOCNO>
	<brief_summary>We want compare Taxol give weekly Taxotere give every 3 week comination Xeloda . We go compare time treatment failure quality life .</brief_summary>
	<brief_title>Weekly Taxol Plus Xeloda® v Taxotere q3wk Plus Xeloda® Treatment Metastatic BC</brief_title>
	<detailed_description>Open label randomize multicentre phase II/III trial . It intend include patient usually include clinical trial disease measurable lesion . In breast cancer bulk patient metastatic disease present bone metastasis difficult evaluate respect response . In study one main objective include kind everyday patient see clinic . Because use TTF primary endpoint . Skeletal event require radiotherapy major change pain medication define treatment failure cause stop treatment even absence radiological finding . A : weekly Taxol® plus Xeloda® day 1-14 q 3w B : Taxotere® q 3w plus Xeloda® day 1-14 q 3w Patients randomize equally two arm . Concomitant therapy : Simultaneous use bisphosphonates allow , treatment initiate least four week study entry .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Morphologically prove breast carcinoma Written inform patient consent Measurable and/or evaluable disease Measurable disease define least one lesion accurately measure least one dimension ≥20 mm conventional technique , ≥10 mm spiral CT scan ) define section 8 . Evaluable metastasis . Lytic bone metastases site recurrence allow evaluate response accord WHOcriteria reporting response bone metastasis . Age 18 year old ECOG Performance Status 02 Life expectancy least three month Adequate cardiac function Adequate hematological , renal hepatic function , define : White blood cell count &gt; 3.9 x 109/L Trombocytes &gt; 100 x 109/L Serum creatinine &lt; 1.25 x ULN* Bilirubin &lt; 1.5 ULN If alkaline phosphatase ( ALP ) normal ALAT &lt; 3.5 ULN ASAT &lt; 3.5 ULN If alkaline phosphatase ( ALP ) &gt; 2.5 ULN ALAT &lt; 1.5 ULN ASAT &lt; 1.5 ULN Recurrencefree interval less one year , previous adjuvant neoadjuvant regimen contain taxane Neoplasm breast carcinoma , except nonmelanoma skin cancer curatively treat carcinoma situ cervix , diagnose past five year Pregnancy lactation Known brain metastasis Preexisting motor sensory neuropathy ≥ grade 2 accord NCI CTC 2.0 criterion ( severe paresthesia and/or mild weakness , bad ) Severe hepatic renal impairment ( capecitabine : calculated creatinine clearance 30 ml/min ; calculation , see p. 5.1.4 ) allow adequate use propose regimen History know dihydropyrimidine dehydrogenase ( DPD ) deficiency ( severe reaction previous treatment fluorouracil ) Active infection serious underlie medical condition would impair ability patient receive protocol treatment , include prior allergic reaction drug contain cremophor , teniposide , cyclosporine vitamin K Dementia significantly alter mental status would prohibit understanding give informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Qulaity life</keyword>
</DOC>